DUBLIN, IRELAND, Aug. 26, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024. Dan Carestio, President and CEO of STERIS will present at 1:50 p.m. Eastern Time. A simultaneous webcast and replay of the Company's presentation will be available on STERIS's investor relations website at www.steris-ir.com. STERIS is a leading global provider of products an ...

I I F ■ F Matteo Colombo Investment update Following my last publication on STERIS plc (NYSE:STE) the stock is +2.5% in the green after backing and filling into congestion. The company's Q1 FY'25 numbers gleaned several insights that provide a comprehensive view into what to expect for the remainder of the financial year. That report, titled "Remains on track for strong fiscal 24", outlined several bullish factors in the debate, including: STE staged an upside move off lows in early '23, where I advocated b ...

Have you evaluated the performance of Steris' (STE) international operations for the quarter ending June 2024? Given the extensive global presence of this medical products maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ | --- | --- | |----------------------------------------------------------------|----------------------------------------- ...

STERIS plc (STE) reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of $2.03, up 10.3% from the year-ago quarter's figure. The figure surpassed the Zacks Consensus Estimate by 2 cents. The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges, among others. The company's GAAP EPS was $1.41, up 7.6% from the year-ago level of $1.31. Revenues in Detail Revenues of $1.28 billion ...

STERIS plc (NYSE:STE) Q1 2025 Earnings Conference Call August 7, 2024 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President & Chief Financial Officer Dan Carestio - President & Chief Executive Officer Conference Call Participants Brett Fishbin - KeyBanc Mike Matson - Needham & Company Michael Polark - Wolfe Research Jason Bednar - Piper Sandler Dave Turkaly - JMP Securities Operator Good morning, and welcome to the STERIS First Quarter of 2025 Earnings Call. [ ...

Steris (STE) reported $1.28 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 0.4%. EPS of $2.03 for the same period compares to $2.00 a year ago. The reported revenue represents a surprise of +1.47% over the Zacks Consensus Estimate of $1.26 billion. With the consensus EPS estimate being $2.01, the EPS surprise was +1.00%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

Steris (STE) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 1%. A quarter ago, it was expected that this medical products maker would post earnings of $2.41 per share when it actually produced earnings of $2.41, delivering no surprise. Over the last four quarters, the company has surpas ...

Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2025 First Quarter • Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% • As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 • Fiscal 2025 outlook reiterated DUBLIN, IRELAND - (August 6, 2024) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuin ...

Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1. ...